Responses
Rheumatoid arthritis
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Compose a Response to This Article
Other responses
No responses have been published for this article.